# A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Source: https://onco.cc/trials/nct06952803/  
OnCo record `nct06952803` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06952803 as recruiting, last updated 2026-09-18. Enrolment is 700 planned participants, an estimate. Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT). Primary measures include Metastasis-free survival (MFS). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: EvoPAR-Prostate02
- Tags: ctgov-ingest
- Registry id: NCT06952803
- Phase: 3
- Setting: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).
- Sponsor: AstraZeneca

## Sources

- ClinicalTrials.gov NCT06952803: https://clinicaltrials.gov/study/NCT06952803

## Connected records

- cancers: [Localised prostate cancer, high and very high risk](https://onco.cc/cancers/prostate-high-risk/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06952803.json